␣-Synuclein is an abundant presynaptic protein that binds to phospholipids and synaptic vesicles. Physiologically, ␣-synuclein functions as a SNARE-protein chaperone that promotes SNARE-complex assembly for neurotransmitter release. Pathologically, ␣-synuclein mutations and ␣-synuclein overexpression cause Parkinson's disease, and aggregates of ␣-synuclein are found as Lewy bodies in multiple neurodegenerative disorders ("synucleinopathies"). The relation of the physiological functions to the pathological effects of ␣-synuclein remains unclear. As an initial avenue of addressing this question, we here systematically examined the effect of ␣-synuclein mutations on its physiological and pathological activities. We generated 26 ␣-synuclein mutants spanning the entire molecule, and analyzed them compared with wild-type ␣-synuclein in seven assays that range from biochemical studies with purified ␣-synuclein, to analyses of ␣-synuclein expression in cultured neurons, to examinations of the effects of virally expressed ␣-synuclein introduced into the mouse substantia nigra by stereotactic injections. We found that both the N-terminal and C-terminal sequences of ␣-synuclein were required for its physiological function as SNARE-complex chaperone, but that these sequences were not essential for its neuropathological effects. In contrast, point mutations in the central region of ␣-synuclein, referred to as nonamyloid ␤ component (residues 61-95), as well as point mutations linked to Parkinson's disease (A30P, E46K, and A53T) increased the neurotoxicity of ␣-synuclein but did not affect its physiological function in SNARE-complex assembly. Thus, our data show that the physiological function of ␣-synuclein, although protective of neurodegeneration in some contexts, is fundamentally distinct from its neuropathological effects, thereby dissociating the two activities of ␣-synuclein.
Introduction
␣-Synuclein is a small abundant neuronal protein that is natively unstructured, but folds into amphipathic ␣-helices in the presence of negatively charged lipids (Maroteaux et al., 1988; Perrin et al., 2000) , binds to synaptobrevin-2/VAMP2 (Burré et al., 2010) , and localizes to synaptic vesicles in nerve terminals (Iwai et al., 1995) . In vitro and in cultured cells and neurons, ␣-synuclein promotes SNARE-complex assembly (Burré et al., 2010) . Three synuclein genes are expressed in mammals that encode ␣-synuclein, ␤-synuclein, and ␥-synuclein. ␣/␤/␥-Synuclein triple knock-out (KO) mice develop progressive neuropathology and motor impairments, die prematurely, and exhibit impaired SNARE-complex assembly, which is consistent with the idea that ␣-synuclein functions as a SNARE-complex chaperone (Burré et al., 2010; Greten-Harrison et al., 2010) .
Aggregates of ␣-synuclein are found in age-dependent disorders called synucleinopathies, including Parkinson's disease (PD), Alzheimer's disease, multiple system atrophy, and dementia with Lewy bodies (Spillantini and Goedert, 2000; Masliah et al., 2001 ). Both point mutations in ␣-synuclein (A30P, E46K, A53T) (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz et al., 2004) and duplication or triplication of the ␣-synuclein gene (Singleton et al., 2003; Ibáñez et al., 2004) produce PD. PD-linked ␣-synuclein mutations affect ␣-synuclein fibril formation in vitro (Conway et al., 1998 (Conway et al., , 2000 Narhi et al., 1999; Greenbaum et al., 2005; Fredenburg et al., 2007; Yonetani et al., 2009) , and ␣-synuclein oligomers are toxic to neurons in vivo (Kayed et al., 2003; Lindersson et al., 2004; Tsika et al., 2010; Colla et al., 2012) , suggesting that a toxic gain-of-function effect of ␣-synuclein may produce the neurodegeneration in PD and other synucleinopathies. At least in some instances, however, the physiological function of ␣-synuclein in promoting SNAREcomplex assembly protects against neurodegeneration instead of promoting it (Chandra et al., 2005) . Specifically, modest overexpression of ␣-synuclein rescues the lethal neurodegeneration caused by deletion of CSP␣ (cysteine string protein ␣), a chaper-one for the SNARE-protein SNAP-25 (Sharma et al., 2011b) . ␣-Synuclein blocks neurodegeneration in CSP␣ KO mice by compensating for the decreased SNARE-complex assembly induced by the loss of SNAP-25 in these mice (Sharma et al., 2011a) . Thus, the question arises whether ␣-synuclein performs independent physiological functions and pathological actions, or whether pathology induced by ␣-synuclein mutations or overexpression is related to a loss of its overall physiological function.
While the pathology caused by PD-linked ␣-synuclein mutants has been extensively compared with wild-type (WT) ␣-synuclein, few studies have performed systematic targeted mutagenesis experiments of ␣-synuclein to compare the consequences of various mutations for the neuropathogenic effects and physiological functions of ␣-synuclein. Here, we set out to fill this gap in our understanding, and to clarify whether pathology in synucleinopathies is caused by a loss or gain of function of ␣-synuclein. Toward this goal, we generated mutants of all sequence regions of human ␣-synuclein, and examined their properties using a variety of functional and pathological readouts. Our data suggest that the physiological function and neuropathogenic effects of ␣-synuclein are mediated by molecularly distinct processes.
Materials and Methods

␣-Synuclein expression vectors
A c-myc epitope with a 4 aa linker was introduced into all expression vectors, resulting in the following N-terminal sequence: EQKLISEEDLGSGS. Introduction of stop codons or point mutations were accomplished by sitedirected mutagenesis. All myc-tagged ␣-synuclein mutants were inserted into either pGEX-KG for bacterial expression [with an N-terminal tobacco etch virus (TEV) cleavage site right before the myc epitope tag, leaving an extra N-terminal glycine upon proteolytic removal of the GST moiety], pCMV5 for expression in HEK293T cells, FUW for lentiviral expression in neuronal culture, or L302 (containing an IRES-driven GFP reporter) for lentiviral expression in substantia nigra upon stereotactic injection.
Mice
Synuclein triple KO mice, synaptobrevin-2 KO mice, and WT mice maintained on C57BL/6 background were maintained and bred as described previously (Schoch et al., 2001; Burré et al., 2010; Xu et al., 2012) . Mice of either sex were used for stereotactic injections or primary neuronal culture. The animal protocols used in this study, as well as the overall mouse husbandry practices, were approved by the respective institutional animal care and use committees at University of Texas Southwestern Medical Center and Stanford University.
Primary mouse neuronal culture
Mouse hippocampal neurons were cultured from newborn mice essentially as described previously (Tang et al., 2006; Maximov et al., 2007) . Brain regions were dissected in ice-cold HBSS, dissociated by trypsinization (0.05% trypsin-EDTA for 10 min at 37°C), triturated with a siliconized pipette, and plated (100 ml) onto a 12 mm coverslip (for immunofluorescence) or on 12-well plastic dishes, coated for at least 30 min with Matrigel (BD Biosciences). Plating medium (MEM, Invitrogen) supplemented with 5 g/L glucose, 0.2 g/L NaHCO 3 (Sigma-Aldrich), 0.1 g/L transferrin (Calbiochem), 0.25 g/L insulin (Sigma-Aldrich), 0.3 g/L L-glutamine (Invitrogen), and 10% fetal bovine serum was replaced with growth medium (MEM, Invitrogen) containing 5 g/L glucose, 0.2 g/L NaHCO 3 (Sigma-Aldrich), 0.1 g/L transferrin (Calbiochem), 0.3 g/L L-glutamine (Invitrogen), 5% fetal bovine serum, 2% B-27 supplement (Invitrogen), and 2 mM cytosine arabinoside (Sigma-Aldrich) 24 -48 h after plating. Cultured neurons were transduced with recombinant lentiviruses and used for experiments as indicated.
Lentiviral vector production, transduction, and expression
Lentiviral vector (FUW containing myc-tagged ␣-synuclein mutants or empty vector), VSVG (vesicular stomatitis virus glycoprotein), and ⌬8.9 HIV-1 packaging vectors were cotransfected in a 1:1:1 molar ratio into HEK293T cells (ATCC) in neuronal growth medium using Fugene-6 (Roche). Medium containing the viral particles was collected 48 h later and centrifuged for 10 min at 2000 rpm to remove any cellular debris. The supernatant containing virions was added to cultured neurons at 7 DIV, and the expression of the recombinant proteins was monitored at 21 DIV.
Expression of ␣-synuclein mutants in substantia nigra
Lentiviral vector L302 containing an IRES-driven GFP reporter (containing myc-tagged ␣-synuclein mutants), VSVG, Rev, and RRE (Revresponsive element) were cotransfected in a 1:1:1:1 molar ratio into HEK293T cells as described above. Viral particles were concentrated by centrifugation at 50,000 g av for 90 min. The viral pellet was resuspended in neuronal medium (at 1 ⁄50 of the precentrifugation volume) containing 4 mg/ml polybrene (Sigma-Aldrich), snap-frozen in liquid N 2 , and kept at Ϫ80°C.
CD1 mice (P40 -P45, Charles River Laboratories) were anesthetized by intraperitoneal injection of 125-250 mg/kg Avertin (tribromoethanol, Sigma-Aldrich). One microliter of viral solution was delivered through a glass pipette at a flow rate of 0.15 l/min unilaterally (left hemisphere) at the following coordinates: anteroposterior, 2.6 -3.3 mm posterior to bregma (determined based on lambda-to-bregma distance of each mouse); lateral, 1 mm from midline suture; ventral, 4.2 mm below brain surface. Following 10 d of recovery, analysis of mouse behavior was commenced.
Behavioral studies
Beam-walking test was used to record deficits in balance and limb control (accuracy and strength in limb placement). Animal's ability to navigate across a beam to return to its home cage was tested using a wooden dowel (cylindrical beam 60 cm in length, 1 cm in diameter). The beam was steadily fixed on both ends 40 cm above the ground leading to a small cage filled with bedding from the animal's home cage. Mice were placed onto one side of the beam and were left to cross the beam to reach the cage. Mice that escaped into the cage were picked up and placed on the opposite side again for a total of three trials with 1 min intertrial intervals. Number of footslips for each mouse per trial was scored. Forceplate actometry, a sensitive and quantitative method (Fowler et al., 2001) , was used to document changes in locomotor activity induced by injection of lentivirus expressing ␣-synuclein mutants in substantia nigra. From the force plate traces/coordinate records, low-mobility bouts and spatial confinement per 6 min session were determined.
Immunofluorescence and immunohistochemistry
Cultured neurons infected with lentiviruses encoding myc-tagged ␣-synuclein, or transfected HEK293T cells, were washed three times with PBS, and fixed for 20 min at room temperature in PBS containing 4% paraformaldehyde. Following three washes with PBS, the fixed cultures were permeabilized for 5 min (PBS containing 0.1% Triton X-100, Sigma-Aldrich). Cells were washed three times with PBS and blocked for 20 min with 5% BSA in PBS. ␣-Synuclein expression was monitored using myc antibodies (monoclonal, 1:200; Santa Cruz Biotechnology). Synapsin antibodies (E028, polyclonal, 1:1000) were used as synaptic marker, incubated each overnight at 4°C in 1% BSA in PBS, and followed by anti-rabbit Alexa 633 and anti-mouse Alexa 488 secondary antibody (1:500 each), both incubated for 1 h each in blocking solution. The coverslips were rinsed six times with PBS, mounted on slides in Vectashield aqueous mounting medium (Vector Laboratories), and stored at 4°C. Laser scanning confocal microscopy was performed to compare localization, with serial excitation at 488 and 633 nm on a Leica TCSSP-2 inverted microscope.
For immunohistochemical studies, anesthetized mice were perfused with ice-cold 4% paraformaldehyde in PBS, followed by removal of the brain and overnight fixation in 4% paraformaldehyde in PBS (room temperature). Fixed brains were cryopreserved in 30% sucrose in PBS for 2 d and frozen in Tissue-Tek Optimal Cutting Temperature embedding medium (Sakura Finetechnical). Sagittal brain sections (20 mm) were cut at Ϫ20°C (Leica CM3050S cryostat), picked up on slides, and heat adhered at 37°C for 30 min. For immunostaining, slides were incubated in blocking solution (3% BSA, 0.1% Triton X-100 in PBS) for 1 h followed by overnight incubation with primary antibodies (4°C). Slides were washed three times in PBS (5 min each) and incubated in blocking buffer containing Alexa Fluor 488-coupled, 546-coupled, or 633-coupled secondary antibodies (Invitrogen) for 3 h at room temperature. Following six washes in PBS, slides were mounted with Vectashield hard-set mounting medium with DAPI (Vector Laboratories) followed by fluorescence microscopy.
All quantitations of immunofluorescence images were done with the image processing and analysis software ImageJ (National Institutes of Health). Synaptic colocalization in neuronal culture was assessed using Pearson's coefficient, with translated pictures used for background subtraction. In mouse brains injected with ␣-synuclein-expressing lentiviruses, total tyrosine hydroxylase (TH)-positive neurons, NeuN-positive puncta, and DAPI puncta were counted in each section containing GFP fluorescence. NeuN puncta were normalized to total DAPI puncta in the same brain section. Image acquisition and thresholding parameters were kept constant across each experiment.
Immunoblotting and immunoprecipitation
Either transfected HEK293T cells or cultured neurons were solubilized in PBS, pH 7.4, containing 0.15% Triton X-100 and protease inhibitors (Roche). Following centrifugation at 16,000 g av for 20 min at 4°C, the clarified lysate was used for immunoblotting (after addition of 2ϫ SDS sample buffer containing 100 mM DTT) or subjected to immunoprecipitation. Immunoprecipitation was performed with the indicated primary antibodies and 50 l of a 50% slurry of protein-A Sepharose beads (GE Healthcare) for 2 h at 4°C. Control immunoprecipitations were performed with preimmune sera. Following five washes with 1 ml of the extraction buffer, bound proteins were eluted with 2ϫ SDS sample buffer containing 100 mM DTT and boiled for 20 min at 100°C. Coprecipitated proteins were separated by SDS-PAGE, with 5% of the input in the indicated lane.
To retain ␣-synuclein truncations on the nitrocellulose membranes, membranes were dried for 1 h at room temperature and fixed for 15 min at room temperature in 0.2% glutaraldehyde in PBS. Membranes were washed 3ϫ with TBS-T and treated as above.
Quantitation of SNARE-complexes as high molecular mass bands
Whole brains or cortices were homogenized in ice-cold PBS, and immediately dissolved in 2ϫ SDS sample buffer. The lysates were subjected to SDS-PAGE and immunoblotting with antibodies to SNAP-25 (SMI81) and polyclonal antibodies to synaptobrevin-2 (P939) and syntaxin-1 (438B). To measure total SNARE protein levels, samples were boiled for 20 min at 100°C. SDS-resistant SNARE-complexes were defined as the immunoreactive material Ͼ40 kDa that was absent from boiled samples (Hayashi et al., 1994) .
Recombinant ␣-synuclein expression
All proteins were expressed in bacteria (BL21 strain) as GST fusion proteins in modified pGEX-KG vectors (GE Healthcare), essentially as described previously (Burré et al., 2010) . Bacteria were grown to optical density of 0.5 (measured at 600 nm), and protein expression was induced with 0.05 mM isopropyl-Dthiogalactopyranoside (IPTG) for 6 h at room temperature. Bacteria were harvested by centrifugation for 20 min at 4000 rpm and 4°C, and pellets were resuspended in solubilization buffer [PBS, 0.5 mg/ml lysozyme, 1 mM PMSF, 1 mM EDTA, DNase, and an EDTA-free protease inhibitor mixture (Roche)]. Cells were broken by sonication (3 ϫ 15 pulses, 50% output), and insoluble material was removed by centrifugation for 20 min at 7000 g av at 4°C. Proteins were affinity-purified using glutathione Sepharose bead (GE Healthcare) incubation overnight at 4°C, followed by TEV cleavage (10 U/mg protein) for 4 h at 22°C.
Lipid binding
Liposome preparation. Liposomes were always prepared on the day of usage, essentially as described previously (Burré et al., 2010) . Either 500 Figure 1 . ␣-Synuclein mutagenesis strategy and experimental scheme. A, Mutagenesis strategy. Mutagenesis of ␣-synuclein was aimed at (1) introducing proline residues at conserved positions within the 11-mer sequences that comprise most of ␣-synuclein to break amphiphatic helices that mediate the lipid binding of ␣-synuclein (in red); (2) replicating PD mutants (in green); and (3) deleting subdomains by truncation mutations (yellow bars). B, Purification of recombinant myc-tagged WT ␣-synuclein and mutants of ␣-synuclein (top, Coomassie staining; bottom, immunoblotting with c-myc antibody). C, Experimental scheme. WT and mutant ␣-synucleins were subjected to a variety of in vitro and in vivo assays as depicted. g brain L-␣-phosphatidylcholine (PC, Avanti Polar Lipids) or 345 g of PC and 155 g of brain L-␣-phosphatidylserine (Avanti Polar Lipids) were mixed with 2.5 g of 1-oleoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphocholine (NBD, Avanti Polar Lipids) in a glass tube. The lipid mixture was dried under a nitrogen stream and for 2 h in a speed vacuum concentrator. To form unilamellar small vesicles, dried lipids were solubilized in 500 l of 20 mM phosphate buffer, pH 7.4, vortexed for 2 min, and then sonicated for 3 ϫ 15 pulses at 1 s intervals and 38% sonicator output.
Lipid-binding assay. At room temperature, 3.5 M ␣-synuclein was incubated with liposomes at 1:363 molar ratio for 2 h. In a centrifugation tube, 100 l of protein sample was mixed with 100 l of 20 mM phosphate buffer, pH 7.4, and 200 l of 80% Accudenz reagent (Accurate Chemical & Scientific) in the same buffer (40% final density), and carefully overlaid with 200 l of 35% Accudenz reagent, 200 l of 30% Accudenz reagent, and 30 l of buffer. To achieve separation of bound and nonbound proteins, gradients were centrifuged for 3 h at 280,000 g av and 100 l of fractions were collected from the top to the bottom of the gradient. The distribution of the liposomes in the gradient was determined by measuring the fluorescence of the lipid derivative NBD in each fraction using a fluorescence plate reader (excitation at 464 nm, emission at 531 nm; Mithras LB 940, Berthold Technologies). For analysis of protein distribution within the gradient, 10 l of 5ϫ SDS sample buffer containing 100 mM DTT were mixed with 100 l of protein sample, and 20 l were separated by SDS-PAGE and immunoblotted for SNARE proteins and ␣-synuclein.
Protein quantitation
All quantitative immunoblotting experiments were performed with iodinated secondary antibodies as described previously (Rosahl et al., 1995) . Samples were separated by SDS-PAGE, and transferred onto nitrocellulose membranes. Blots were blocked in Tris-buffered saline con- taining 0.1% Tween-20 (Sigma-Aldrich) and 3% fat-free milk for 30 min at room temperature. The blocked membrane was incubated in blocking buffer containing primary antibody overnight at 4°C, followed by three washes in blocking buffer. The washed membrane was incubated in blocking buffer containing either horseradish peroxidase (HRP)-conjugated secondary antibody (1:8000; MP Biomedicals) for 1 h at room temperature, or 125 I-labeled secondary antibody (1:1000; PerkinElmer) overnight at room temperature. HRP immunoblots were developed using enhanced chemiluminescence (GE Healthcare).
125
I blots were exposed to a PhosphorImager screen (GE Healthcare) overnight and scanned using a Typhoon scanner (GE Healthcare), followed by quantitation with ImageQuant software (GE Healthcare).
Antibodies
Monoclonal antibodies used were ␤-actin (1:5000; A1978, Sigma-Aldrich), myc (1:200; Santa Cruz Biotechnology), NeuN (MAB377, Millipore), Figure 3 . Synaptic targeting of ␣-synuclein mutants. A, B, Synaptic localization of ␣-synuclein in cultured neurons from WT and synaptobrevin-2 KO (Syb2 KO) mice, and of Syb2 in cultured neurons from WT and synuclein triple knock-out (TKO) mice (A). Cultured neurons were immunostained with antibodies to endogenous ␣-synuclein (left, green), endogenous Syb2 (right, green), and synapsin (red). Colocalization was quantitated using Pearson's coefficient (B). C-E, Synaptic localization of WT and mutant ␣-synucleins. Hippocampal WT cultures were infected with lentivirus expressing WT and mutant ␣-synucleins at 7 DIV, and were immunostained at 21 DIV using antibodies to c-myc (green) and to synapsin (as a synaptic marker, red). C shows magnified images of WT and A30P ␣-synuclein to highlight differences in synaptic targeting. Synaptic localization was quantitated using Pearson's coefficient (E). Note that deletion mutants 1-42 and 9 -42 were not expressed. Data are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001 by Student's t test; n ϭ 3 independent cultures for A, and n ϭ 7-9 independent cultures for D).
SNAP-25 (1:5000; SMI81, Sternberger Monoclonals; 1:1000; cl. 71.1, Synaptic Systems), synaptobrevin-2 (1:1000; cl. 69.1, Synaptic Systems), ␣-synuclein (1:1000; BD Biosciences), syntaxin-1 (1:1000; cl. HPC-1, Synaptic Systems). Polyclonal antibodies used were myc (1:1000; SigmaAldrich), synapsin (1:1000; E028), syntaxin-1 (1:1000; 438B), and TH (1: 400; AB112, Abcam).
Quantitation of functional and pathological indices
Average function was calculated from data obtained for lipid binding ( percentage of WT), synaptic targeting ( percentage of WT), synaptobrevin-2 binding (100 or 0%), and SNARE-complex assembly ( percentage of WT). Average pathology was calculated from data obtained for aggregation in transfected HEK cells ( percentage of WT), beamwalk analysis ( percentage of WT), spatial confinement and low-mobility bouts obtained by force plate analysis ( percentage of WT), and analysis of dopaminergic and total neuron loss in substantia nigra ( percentage of WT).
Statistical analyses
Unless stated otherwise, coimmunoprecipitation experiments are shown as recovered protein (relative to the input), which was first normalized to the immunoprecipitated protein and then normalized to the control. All other data shown are means Ϯ SEMs, and were statistically analyzed by Student's unpaired two-tailed t test to compare the data groups. n refers to the number of different cultures or mice used in each group in separate experiments, or to the number of independent in vitro experiments.
Results
Design and generation of ␣-synuclein mutants ␣-Synuclein is a small protein (140 residues) composed of an N-terminal region (residues 1-95 accounting for ϳ 2 ⁄3 of the molecule), which binds to membranes in an ␣-helical conformation, and a C-terminal region (residues 96 -140), which remains unstructured upon membrane-binding, but is phosphorylated and binds to synaptobrevin-2 ( , 2010) . The N-terminal region of ␣-synuclein contains seven imperfect 11 aa repeats with a KTKEGV consensus sequence. Upon membrane binding, the N-terminal region forms either two ␣-helices connected by a flexible linker or a single extended ␣-helix with a possible continuous switch between the two states under physiological conditions (Chandra et al., 2003; Bisaglia et al., 2005; Borbat et al., 2006; Bortolus et al., 2008; Georgieva et al., 2010; Lokappa and Ulmer, 2011) .
To investigate the relationship between the physiological function of ␣-synuclein in SNARE-complex assembly and its pathological effects in neurons, we systematically mutated key residues and sequences of human ␣-synuclein (Fig. 1A) . We generated two types of ␣-synuclein mutations: (1) point mutations that introduce proline substitutions at defined positions in the 11 aa repeats to impair ␣-helix formation or to replicate PD mutations, and (2) deletion mutations that remove parts of the overall protein (Fig. 1A) . In this manner, we produced 26 different ␣-synuclein mutants. All ␣-synuclein mutants were tagged with a myc epitope to allow accurate quantitation of the levels of the various mutant proteins (Fig.  1B) . We then examined all ␣-synuclein mutants by seven assays that range from experiments using purified proteins in in vitro systems to experiments in cultured neurons and in vivo in mice, thus producing 189 principal measured parameters (Fig.  1C) . These seven assays include analyses of the biochemical activities of ␣-synuclein (phospholipid binding, aggregation, and synaptobrevin-binding), the targeting of ␣-synuclein and its mutants to synapses, analysis of their effects on SNARE-complex assembly, and examination of the in vivo effects of lentivirally expressed ␣-synuclein and its mutants (Fig. 1C) .
Lipid binding of ␣-synuclein is mediated by its two ␣-helices ␣-Synuclein cycles between a cytosolic monomeric state and a membrane-bound state that localizes ␣-synuclein to synaptic vesicles (Iwai et al., 1995) . Thus, any change in membrane affinity may alter its function. To measure the ability of point and truncation mutants of ␣-synuclein to bind to phospholipid vesicles, we used purified myc-tagged ␣-synuclein proteins (Fig. 1 B) and a previously described liposome flotation assay (Fig. 2 A, B ) (Burré et al., 2010) . When ␣-synuclein was assayed without liposomes or in the presence of phosphatidylcholine liposomes, which are not negatively charged, no shift of ␣-synuclein to the liposome-containing top gradient fractions was detected (Fig.  2C) . Upon introduction of 30% phosphatidylserine into phosphatidylcholine liposomes, the majority of WT ␣-synuclein was present in the liposome fraction, unaffected by the presence or absence of the N-terminal myc epitope-tag (Fig. 2 D) . All proline mutations except for G41P reduced the ability of ␣-synuclein to bind to phospholipid vesicles, presumably due to breaking one of the two ␣-helices (Chandra et al., 2003; Bussell and Eliezer, 2004; , whereas the two PD mutations A53T and E46K did not impair lipid binding (Fig. 2 D) . Deletion of the unstructured C terminus of ␣-synuclein had no effect on lipid binding, but deletion of either one of the two ␣-helices abolished lipid binding (Fig. 2 E) . Notably, deletion of the N-terminal 7 residues that precede the first 11 aa repeat of ␣-synuclein also dramatically reduced lipid binding (Fig. 2 E) . These liposomebinding results were quantified in multiple independent experiments, enabling an accurate determination of the percentage of total protein that was bound (Fig. 2 F) . The quantitations revealed that, although the proline mutations impair phospholipid binding, they do not block binding in the same manner as complete deletions of one of the two ␣-helices, suggesting that the proline mutations only decrease the affinity of ␣-synuclein for phospholipids, but do not abolish binding. These quantitations also indicate that proline mutations in all parts of the two ␣-helices have similar detrimental effects (except for the G41P mutation, which appeared to be innocuous), suggesting that both ␣-helices of ␣-synuclein and all segments of these ␣-helices are equally important for phospholipid binding.
Effect of ␣-synuclein mutations on ␣-synuclein localization ␣-Synuclein is highly enriched in presynaptic terminals (Iwai et al., 1995) , consistent with its role in promoting SNARE-complex assembly (Burré et al., 2010) . Immunolocalization studies in cultured neurons from WT mice revealed a high degree of ␣-synuclein colocalization with the synaptic vesicle marker synapsin, measured using Pearson's coefficient (Fig. 3 A, B) . The ␣-synuclein colocalization was almost as high as that of the synaptic vesicle protein synaptobrevin-2. In cultured neurons from synaptobrevin-2 KO mice (Schoch et al., 2001 ), the synaptic localization of ␣-synuclein was significantly decreased (Fig. 3 A, B) . However, no change in synaptobrevin-2 localization was de- Figure 5 . Effects of ␣-synuclein mutations on the ␣-synuclein mediated catalysis of SNARE-complex assembly measured via the SDS-resistance of SNARE complexes. A, B, Cultured neurons from synuclein triple KO (TKO) mice were infected at 7DIV with lentivirus overexpressing WT and mutant ␣-synuclein. At 21 DIV, neurons were harvested and SNARE-complexes were measured as the high molecular mass bands immunoreactive for SNAP-25, which disappear upon boiling. ␣-Syn, ␣-synuclein; Synt-1, syntaxin-1; Syb2, synaptobrevin-2. B, Quantitation of SNARE-complex assembly upon overexpression of WT and mutant ␣-synucleins, normalized to control levels. Data are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001 by Student's t test; n ϭ 3 independent cultures).
tected in neurons from ␣/␤/␥-synuclein triple KO mice. Together, these experiments not only support the preferential localization of ␣-synuclein in presynaptic terminals adjacent to synapsin, but also suggest that this localization depends, at least in part, on the binding of ␣-synuclein to synaptobrevin-2 (Burré et al., 2010) , whereas the localization of synaptobrevin-2 is independent of synucleins.
We then asked which ␣-synuclein sequences may be necessary for its presynaptic localization. To address this question, we expressed WT ␣-synuclein and the 26 ␣-synuclein mutants in cultured cortical mouse neurons using lentiviral infection at 7 DIV, and analyzed the localization of the expressed ␣-synuclein proteins by immunocytochemistry at 21 DIV (Fig. 3C,D) . These experiments were independently repeated multiple times and quantified by image analysis in a blinded manner, allowing a numerical description of the degree of presynaptic targeting of each ␣-synuclein mutant (Fig. 3E) .
Exogenous WT myc-tagged ␣-synuclein exhibited the same degree of colocalization with endogenous synapsin as endogenous ␣-synuclein (Fig. 3 B, E) . Surprisingly, most proline mutants that had a profound effect on lipid binding produced at best a marginal decrease in the presynaptic targeting of ␣-synuclein. Only the PD mutant A30P showed a significant (ϳ25%) reduction of presynaptic targeting (Fig. 3C-E) , suggesting an additional defect besides the impaired lipid binding. Most truncation mutants, however, significantly decreased the presynaptic localization of ␣-synuclein, demonstrating that both ␣-helices of ␣-synuclein are essential for ␣-synuclein targeting to synaptic vesicles (Fig. 3 D, E) .
The C-terminal ␣-synuclein sequence is essential for synaptobrevin-2 binding and for promoting SNARE-complex assembly
To test which ␣-synuclein mutations impair binding to synaptobrevin-2, we transfected HEK293T cells with expression vectors encoding synaptobrevin-2 and WT or mutant ␣-synucleins, and analyzed their interaction using coimmunoprecipitation with antibodies to the myc epitope-tag on the transfected ␣-synucleins (Fig. 4) . No point mutation impaired the coimmunoprecipitation of synaptobrevin-2 with ␣-synuclein (Fig. 4A) . In contrast but in agreement with previous studies (Burré et al., 2010) , truncation mutants lacking the C-terminal ␣-synuclein region did not bind to synaptobrevin-2, whereas truncation mutants of the N-terminal region had no effect (Fig. 4B) .
We next probed the ability of various ␣-synuclein mutants to promote SNARE-complex assembly similar to WT ␣-synuclein. To analyze the effect of ␣-synuclein mutants on SNARE-complex assembly, we expressed the various ␣-synuclein proteins by lentiviral delivery in cultured neurons obtained from triple ␣/␤/␥-synuclein KO mice. We then assayed SNARE-complex assembly using two independent methods: (1) immunoblotting of SDS-resistant SNARE-complexes on SDS-polyacrylamide gels (Hayashi et al., 1994) and (2) coimmunoprecipitating the SNARE proteins synaptobrevin-2 and SNAP-25 with antibodies to the SNAREprotein syntaxin-1 (Figs. 5, 6 ). For both assays, we used quantitative immunoblotting with 125 I-labeled secondary antibodies to measure the levels of the indicated proteins.
Both assays produced the same results. Whereas WT ␣-synuclein potently promoted SNARE-complex assembly as reported previ- Figure 6 . Effects of ␣-synuclein mutations on the ␣-synuclein mediated catalysis of SNARE-complex assembly measured by SNARE protein coimmunoprecipitations. A, B, Cultured neurons obtained as described for Figure 5 were harvested at 21 DIV, and SNARE-complexes were immunoprecipitated with antibodies to syntaxin-1 (Synt-1). Coimmunoprecipitated proteins were immunoblotted for SNAP-25 and synaptobrevin-2 (Syb2) (A). Recovered protein (relative to input) was quantitated and normalized to the immunoprecipitated protein and then to control levels (B). Data are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001 by Student's t test; n ϭ 3 independent cultures).
ously (Burré et al., 2010) , all truncation mutants except for the deletion of the N-terminal 8 ␣-synuclein residues were unable to promote SNARE-complex assembly (Figs. 5, 6 ). Thus, both phospholipid binding mediated by the ␣-helices of ␣-synuclein and synaptobrevin-2 binding mediated by the C-terminal ␣-synuclein sequence (Figs. 2, 4) are required for the ability of ␣-synuclein to promote SNAREcomplex assembly. In contrast to the truncation mutants, only one point mutant of ␣-synuclein, the A30P mutation, impaired the ability of ␣-synuclein to promote SNARE-complex assembly. The others, including the PD mutants E46K and A53T, did not. Thus, partial impairment of phospholipid binding, as observed with most of these point mutants (Fig. 2) , does not by itself block the function of ␣-synuclein to promote SNAREcomplex assembly. The A30P mutation is unique among the ␣-synuclein point mutants in that it did impair SNAREcomplex assembly, possibly due to impaired synaptic targeting (Fig. 3) .
Effect of ␣-synuclein mutations on ␣-synuclein aggregation ␣-Synuclein aggregation into Lewy bodies is a hallmark of PD and other neurodegenerative disorders (Spillantini and Goedert, 2000; Masliah et al., 2001) , raising the question how various ␣-synuclein mutations may alter ␣-synuclein aggregation. To assess the aggregation of WT and mutant ␣-synucleins in an intracellular environment, we overexpressed WT and mutant ␣-synucleins in HEK293T cells and measured the amount of protein produced using quantitative immunoblotting (Fig.  7A,B) . We then used immunostaining with antibodies to the myc epitope-tag on the expressed ␣-synuclein proteins to quantify the formation of ␣-synuclein aggregates (Fig.  7C-E) . 
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HEK cells were transfected with equal amounts of expression vectors encoding WT and mutant ␣-synucleins. Two days after transfection, expression levels were analyzed by immunoblotting with antibodies against the myc-epitope (A) and quantitated as percentage of WT levels (B). C-E, Aggregation of wild-type and mutant ␣-synucleins in the transfected HEK293T cells. Two days after transfection, cells were fixed and immunostained with antibodies against the myc-epitope (C, D). C shows magnified images to highlight differences in aggregation for WT (modest aggregation), 1-95 (highest amount of aggregation), and 42-140 (lowest amount of aggregation) variants of ␣-synuclein. Single-headed arrows mark aggregates. Double-headed arrows indicate areas with no aggregation. Number of immunopositive aggregates per field was quantitated and compared with WT levels (E). Data in B and E are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001 by Student's t test; n ϭ 5 independent cultures).
All ␣-synuclein proteins were expressed at similar levels except for the truncations that included only the single ␣-helix (Fig.  7 A, B) . As expected, all three PD mutations of ␣-synuclein increased the propensity of ␣-synuclein to aggregate (Fig. 7 D, E) . Moreover, consistent with previous results (Liu et al., 2005; Lewis et al., 2010) , C-terminal truncations enhanced ␣-synuclein aggregation ( Fig. 7C-E) . However, most proline substitutions had no effect on ␣-synuclein aggregation except those falling in the so-called "nonamyloid ␤ component" (NAC) region, which is consistent with the known involvement of this region in synuclein aggregation (Giasson et al., 2001; Uversky and Fink, 2002; Du et al., 2003; Waxman et al., 2009) .
WT and mutant ␣-synucleins impair nigrostriatal function in vivo Does either the loss of function of ␣-synuclein, or the aggregation propensity of various ␣-synuclein mutants correlate with their pathological potential in vivo? To monitor the effects of ␣-synuclein mutants on dopaminergic cell survival and mouse motor performance, we stereotactically injected control lentivirus and lentiviruses expressing WT and mutant ␣-synucleins unilaterally into the substantia nigra of WT mice. We performed these injections on postnatal day 40 -45, and monitored motor coordination in the injected mice every 5 d, starting 10 d after injection.
Beamwalk analysis, used to measure balance and motor function, showed that mice injected with ␣-synuclein lentivirus performed worse than mice injected with control virus (Fig. 8) , confirming previous studies that lentiviral overexpression of ␣-synuclein in the substantia nigra produces a dysfunction of motor performance (Lo Bianco et al., 2002; Lauwers et al., 2007; Alerte et al., 2008) . A comparison of the effects of various ␣-synuclein mutants with WT ␣-synuclein revealed that exactly those mutations that increased ␣-synuclein aggregation (Fig. 7) also increased the motor impairment upon nigrostriatal expression (Fig. 8) . The only difference between the aggregation and motor dysfunction effects of ␣-synuclein mutants was that the deletion of the N-terminal 8 residues did not decrease the increased aggregation of C-terminally truncated ␣-synuclein (Fig.  7) , but did prevent the enhancement of motor dysfunction induced by the C-terminal truncation (Fig. 8) .
To assess motor function in mice overexpressing mutant ␣-synuclein in the substantia nigra with a second, independent assay, we monitored these mice on a forceplate actometer (Fowler et al., 2001) (Fig. 9A) . Quantitation of the movements of the mice on the forceplate revealed that WT ␣-synuclein overexpression significantly decreased the mobility of the mice as measured by the number of low-mobility bouts and spatial confinement (Fig. 9B) . Strikingly, the overall pattern of the effects of the mutations in ␣-synuclein on motor impairment was the same as that observed with the beamwalk assay, although the forceplate assay was notably noisier (Fig. 9) . Specifically, the PDassociated mutations, proline substitutions in the NAC region, and C-terminal truncations again enhanced the deleterious effect of overexpressed ␣-synuclein, whereas other mutations had no significant effect on the impairment of motor function by ␣-synuclein. The only difference between the results with the two assays (beamwalk and forceplate) was that the latter also identified a phenotype associated with one of proline substitutions (A19P), and suggested a trend for several other mutations.
␣-Synuclein induced neuronal cell loss in the substantia nigra
Do motor impairments in mice with lentiviral expression of various mutants of ␣-synuclein correlate with neuron loss in the injected area? To assess and compare cell loss in the substantia nigra, we killed mice 45 d after injection, and analyzed dopaminergic cell loss by quantitating TH-positive neurons (Fig. 10) . GFP produced by the viruses via an internal ribosomal entry site was used to identify the injection site. Compared with control injections, brains expressing WT or mutant ␣-synucleins exhibited an overall reduction in the number of dopaminergic neurons in the injected area, suggesting that simple overexpression of ␣-synuclein causes death of dopaminergic neurons (Fig. 10 A, B) . Note that the reduced GFP fluorescence in some brain slices may be caused by loss of infected neurons. We found that ␣-synuclein with PD-associated mutations caused an even larger loss of dopaminergic neurons than WT ␣-synuclein. In addition, the same proline mutations that produced increased ␣-synuclein aggregation (Fig. 7) and impaired motor function in the injected mice (Figs. 8, 9 ) also enhanced the neurotoxic effect of ␣-synuclein (Fig. 10) . The effect of truncated ␣-synuclein, however, was less strong, although even here significant enhancement of the deleterious effects of ␣-synuclein was observed.
Next, we asked whether ␣-synuclein overexpression also affects nondopaminergic neurons in the injected area. Since neurons labeled by NeuN antibodies do not coincide with THexpressing neurons (Cannon and Greenamyre, 2009), we assessed the loss of NeuN-positive neurons by measuring the Figure 8 . Motor defects in mice injected into the substantia nigra pars compacta with lentiviruses expressing WT and mutant ␣-synucleins. Motor defects were assayed using the beamwalk task in which footslips on a beamwalk are measured. Control lentivirus (Control) or lentiviruses expressing WT or mutant ␣-synucleins were stereotactically and unilaterally injected into the substantia nigra pars compacta of 40 -45 d old mice, and mice were analyzed by three rounds of beamwalks per session 45 d after injections. Averaged footslips were recorded. Data are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01 by Student's t test; n ϭ 4 mice).
NeuN/DAPI ratio ( Fig. 10) (Sharma et al., 2011b) . We found a reduction of neuron numbers for WT ␣-synuclein injections compared with control injections. Moreover, we observed a significantly greater reduction of neuron number for PD and NACdomain mutants and the C-terminally truncated ␣-synuclein than for WT ␣-synuclein. These data suggest that overexpression of ␣-synuclein does not specifically induce cell death only in dopaminergic neurons, but is toxic to neurons in general.
Overall, all pathological readouts correlate well with each other in that PD-associated mutations and point mutations in the NAC region as well as C-terminal truncations of ␣-synuclein increase ␣-synuclein aggregation and pathology compared with WT ␣-synuclein. Our data further demonstrate that loss of function of ␣-synuclein does not correlate with increased aggregation propensity/pathology, suggesting that pathology in synucleinopathies may arise from a gain-oftoxic function of ␣-synuclein.
Discussion
Although extensive evidence established a central role for ␣-synuclein in the pathogenesis of neurodegenerative disorders, especially PD (Spillantini and Goedert, 2000; Masliah et al., 2001; Dawson and Dawson, 2003) , the structure-function relations of ␣-synuclein in neurodegeneration remain unknown. Previous studies examining how ␣-synuclein acts in neurodegeneration have rarely correlated in vitro and in vivo (Fig. 8) and killed for histochemical analysis. B, Analysis of low-mobility bouts (top) and spatial confinement (bottom), as calculated from the forceplate data obtained with multiple identically injected mice. Data were plotted as the difference between day 45 and day 10 after injection. Data are means Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01 by Student's t test; n ϭ 4 mice).
activities of ␣-synuclein mutants, and no systematic mutagenesis of the entire molecule was previously performed. Perhaps the most important unaddressed issue, however, is whether the neuropathological effects of ␣-synuclein are related to its physiological functions. This issue is particularly pertinent because the physiological role of ␣-synuclein as a SNARE chaperone can, at least in the context of the neurodegeneration caused by deletion of CSP␣, act to prevent neurodegeneration (Chandra al., 2005) , thus raising the question whether the neuropathological effects of ␣-synuclein are possibly caused by a loss of ␣-synuclein function. The present study attempts to address these issues in a systematic analysis of 26 ␣-synuclein mutants using seven assays for its physiological and pathological actions. The relative effects of the ␣-synuclein mutations on the physiological and pathological actions of ␣-synuclein are summarized in Figure 11 . Overall, our data suggest the following conclusions:
1. There is no correlation between the sequences required for physiological and pathological actions of ␣-synuclein.
Functionally inactive ␣-synuclein does not necessarily produce pathology, whereas many mutations that enhance the neuropathogenic effect of ␣-synuclein do not detectably alter its physiological function as a SNARE chaperone. 2. Full phospholipid binding is not required for the physiological function of ␣-synuclein as a SNARE chaperone at the synapse. Only when Ͼ75% of lipid binding is reduced (e.g., helix 1 is missing), is the physiological function of ␣-synuclein impaired. 3. Synaptic targeting of ␣-synuclein is mediated by both lipid and synaptobrevin-2 binding. 4. The two ␣-helices and the C-terminal region of ␣-synuclein are both essential for its function as a SNARE-chaperone, the former probably because they bind to phospholipids and the latter probably because it binds to synaptobrevin-2. 5. The propensity of ␣-synuclein to aggregate and the pathogenic effects of ␣-synuclein are independent of its N-terminal ␣-helix, but enhanced by point mutations in its central ␣-helix and by deletion of its C-terminal region. Thus, the aggregation and neurotoxicity of ␣-synuclein correlate precisely, suggesting that the two processes are related.
Overall, our data support the notion that aggregation of ␣-synuclein is a central element of its neurotoxicity, extending results from previous studies showing that PD mutants of ␣-synuclein increase the propensity of protofibril or fibril formation of ␣-synuclein (Narhi et al., 1999; Conway et al., 2000; Greenbaum et al., 2005; Ono et al., 2011) and thus pathology in familial PD cases (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz et al., 2004) . Mechanistically, ␣-synuclein aggregation could cause neurotoxicity via at least two pathways. Aggregation of ␣-synuclein could be in itself neurotoxic. The resulting aggregates could damage neurons either as oligomers or as inclusion bodies, thereby impairing neuronal viability (Spillantini and Figure 11 . Summary of the effects of ␣-synuclein mutations on the function and neurotoxic activity of ␣-synuclein. A, ␣-Synuclein domain structure (top) and delineation of ␣-synuclein regions (bottom) that mediate the neurotoxic effects (red) and physiological SNARE-complex assembly function of ␣-synuclein (blue). B, Plot of the effects of alpha-synuclein mutations on the function and neurotoxic activity of ␣-synuclein, normalized to the activity of WT ␣-synuclein. Averaged function was calculated from the data for lipid binding, synaptic targeting, synaptobrevin-2 binding, and SNARE-complex stabilization (Figs. 2-6 ). Averaged pathology was obtained from the data for ␣-synuclein aggregation in HEK cells, footslips on a beamwalk, forceplate analysis, loss of dopaminergic neurons, and loss of total neurons (Figs. 7-10 ). See Materials and Methods for details.
2004; Lansbury and Lashuel, 2006; Tsika et al., 2010; Colla et al., 2012) . Alternatively, ␣-synuclein aggregates could serve to nucleate aggregation of all cellular synucleins, thereby depleting the neuron of synucleins and causing an indirect loss-of-function effect. Although we cannot at present completely rule out the second hypothesis, several lines of evidence argue against it. Possibly the most compelling argument against the indirect loss-of-function hypothesis is the observation that a complete loss of all synucleins in triple ␣/␤/␥-synuclein KO mice does not lead to the same major neuropathology as the overexpression of mutant ␣-synuclein. Specifically, synucleindeficient mice display motor impairments only after 200 d and have no neuronal loss (Burré et al., 2010) , suggesting that the loss-offunction phenotype of ␣-synuclein is a process different from the observed neuropathology.
In agreement with the PD pathology observed in humans (Singleton et al., 2003; Ibáñez et al., 2004) , we found that increased expression of WT ␣-synuclein is sufficient to cause pathology. All three PD mutants aggravated the ␣-synuclein pathology in our assays. We found that the pathology induced by lentiviral expression of ␣-synuclein in the substantia nigra manifests not only as the loss of dopaminergic neurons but also as a loss of other neurons in the injected area. While loss of dopaminergic neurons in the substantia nigra is responsible for motor symptoms in PD (Fahn and Sulzer, 2004) , a variety of other neurons in the central and peripheral nervous system also exhibit signs of pathology in postmortem analysis, suggesting that pathology induced by ␣-synuclein is not limited to dopaminergic neurons (Braak et al., 2007; Baba et al., 2012; Sulzer and Surmeier, 2012) .
Importantly we found that mutations in the NAC region of ␣-synuclein cause pathology in mice similar to familial PD mutations. NAC was originally isolated as a component of ␤-amyloid from brain tissue of Alzheimer's patients (Uéda et al., 1993) , and was later identified as a fragment of ␣-synuclein (Nakajo et al., 1993; Jakes et al., 1994) . The NAC region comprises residues 61-95 of ␣-synuclein, a region that is thought to drive fibril formation (Giasson et al., 2001; Uversky and Fink, 2002; Du et al., 2003; Waxman et al., 2009) . Indeed, all of our mutants falling into this region (G67P, V70P, A78P, T81P, A89P) consistently increased the aggregation and pathogenicity of ␣-synuclein. Introduction of proline residues into the already aggregation-prone NAC region is predicted to reduce its helical content, and may thus shift the conformational equilibrium of ␣-synuclein further toward ␤-sheet content and subsequently toward more fibril formation, resulting in increased pathology. It is interesting that the N-terminal ␣-helix of ␣-synuclein (Chandra et al., 2005) binds more tightly to lipids than the C-terminal ␣-helix (which coincides with the NAC region) (Drescher et al., 2008) , which may account for the greater aggregation propensity of the C-terminal ␣-helix containing the NAC region. Overall, our data suggest that, if familial mutations within the NAC domain were to be found in PD patients, they would cause similarly or more severe phenotypes than those reported for known familial mutations.
C-terminally truncated ␣-synuclein is enriched in human Lewy body extracts (Baba et al., 1998; Tofaris et al., 2003) . Abnormal neurites containing C-terminally truncated ␣-synuclein are present in Alzheimer's disease without conventional Lewy body pathology (Lewis et al., 2010) , and transgenic mice expressing C-terminally truncated forms of human ␣-synuclein develop PD-like symptoms and exhibit PD-like neuronal pathology (Tofaris et al., 2006; Wakamatsu et al., 2008) . Furthermore, coexpression of C-terminal truncated ␣-synuclein enhances fulllength ␣-synuclein-induced pathology (Liu et al., 2005; Ulusoy et al., 2010) . The charge in the unstructured C terminus exerts a profound effect on the aggregation rate of ␣-synuclein (Hoyer et al., 2004; Levitan et al., 2011) , and it has been suggested that interaction between the C-terminal and N-terminal or central NAC region are important in maintaining the natively unfolded structure of ␣-synuclein and in preventing ␣-synuclein from changing conformation (Hong et al., 2011) . Thus, removal of the C terminus may increase aggregation rate and account for the observed pathology in our assays.
In our assays, all proline mutants we analyzed bind to synaptobrevin-2 and reveal similar impairment in lipid binding. However, only the A30P mutation demonstrated decreased synaptic targeting and thus less SNARE-complex stabilization. This result is puzzling, since mutation of the corresponding residues within other 11-mer repeats did not result in a similar loss of function or aggregation of ␣-synuclein. What makes A30P so special? We cannot exclude the possibility that under physiological conditions lipid binding may be influenced by other factors. Alanine 30 may be crucial for proper helix formation of ␣-synuclein. For A30P, loss of helicity upstream and downstream of the substitution has been suggested (Bussell and Eliezer, 2004; , and disruption of helicity in A30P may be more severe than for other proline mutants. Whatever mechanism turns out to be responsible for the increased cytosolic localization of A30P, this increased cytosolic localization compared with other proline mutations within the first ␣-helix of ␣-synuclein may account for the increased pathology: shifting of ␣-synuclein structure toward a more unfolded state may allow increased ␤-sheet formation and aggregation, and thus increased pathology.
Truncation of the N-terminal 8 residues of ␣-synuclein resulted in a 60% decrease in lipid binding. These eight residues are part of the first ␣-helix of ␣-synuclein (Chandra et al., 2003) , but precede its first 11-residue repeat. Surprisingly, deletion of this short helical stretch thus may affect helical structure more severely than introduction of single proline residues within the helix, which disturb protein folding only locally, as shown for A30P (Bussell and Eliezer, 2004; . Similarly, most proline mutants resulted in comparable impairments in lipid binding except for G41P, which did not affect binding of ␣-synuclein to liposomes. Likely, introduction of a helix-breaking proline residue at the very end of helix 1 has less impact on helicity than proline residues in the middle of a helical domain.
In summary, our data suggest that ␣-synuclein pathology is not caused by loss of function of ␣-synuclein, but by gain of toxic function. Since single ␣-synuclein KO mice do not show significant neuropathology (Abeliovich et al., 2000; Schluter et al., 2003) , and knock-out of all three synuclein genes causes significant pathology only in older mice (Burré et al., 2010; GretenHarrison et al., 2010; Anwar et al., 2011) , suppression of ␣-synuclein expression alone may not be pathogenic in humans. Therapies to reduce or abolish ␣-synuclein expression may thus be a worthwhile strategy to decrease or prevent ␣-synucleininduced pathology.
